MedTrace Logo

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)

NCT04117113 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 238

Last updated 2021-09-21

No results posted yet for this study

Summary

The purpose of this study is to collect information from study participants who are hospitalized with an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC). This information will be used to support the development of a new vaccine to prevent Extraintestinal pathogenic Escherichia coli (ExPEC). E. coli bacteria are a leading cause of serious infections. Especially adults older than 60 years have a higher risk of developing such infections. To date, there is no vaccine available to prevent E. coli infections. To support the development of a vaccine, more information about E. coli infections is first needed. This information will be collected in the current study, such as:

* Medical information such as medical history, diagnosis, duration of hospitalization
* Treatment and outcome of the Extraintestinal pathogenic Escherichia coli (ExPEC)
* Laboratory information

Conditions

  • E. Coli Infection

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Innovative Medicines Initiative

    collaborator OTHER

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Miquel B Ekkelenkamp, MD · UMC Utrecht

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2021-01-31
Completion
2021-05-12

Countries

  • United States
  • Canada
  • France
  • Germany
  • Italy
  • Japan
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04117113 on ClinicalTrials.gov